Albendazole Therapy in Postoperative Spinal Cystic Echinococcosis: Evaluating Recurrence and Survival Outcomes Between Short and Long-Term Protocols

##plugins.themes.academic_pro.article.sidebar##

Published Mar 10, 2026
https://doi.org/10.62438/tunismed.v104i01.5749
Download
PDF
Vol. 104 No. 01 (2026): Tunis Med Jan 2026

##plugins.themes.academic_pro.article.main##

Ghassen Gader
Neurosurgery Department, Trauma and Burns Center, Ben Arous, Faculty of Medicine of Tunis, University of Tunis El Manar -1006, Tunis, Tunisia
Mohamed Amine Gharbi
Orthopedic and Trauma Surgery Department, Mongi Slim Hospital, La Marsa, Faculty of Medicine of Tunis, University of Tunis El Manar -1006, Tunis, Tunisia
Mohamed Chaabouni
Radiology Department, MT Kassab Institute of Orthopedics, Ksar Saïd, Faculty of Medicine of Tunis, University of Tunis El Manar -1006, Tunis, Tunisia

Abstract

 


Introduction: The spine is a rare location in cystic echinococcosis even in endemic regions. Surgery is the treatment of choice. There are still uncertainties regarding anthelminthic treatment protocol and duration.


Aim: To evaluate the impact of Albendazole therapy duration on the functional outcome, overall survival and recurrence-free survival in patients operated for spinal cystic echinococcosis (SCE)


Methods: We retrospectively selected patients operated for SCE and collected their epidemiological, clinical, imaging, surgical, and outcomes data.  These patients were categorized into two groups: a 6-month Albendazole therapy after surgery group and an indefinite treatment group. Statistical tests were applied to compare the outcomes.


Results: Thirty-two patients were included, predominantly male (68%) with a mean age of 40 years. The thoracic level was involved in 56%, lumbar in 31% and cervical in 13% of cases. According to Dew/Braithwaite and Lees, 69% of our patients had dumbbell formation, 22% had type 2 and 9% had type 4 lesions. Complete resection was achieved in 50% of cases.18 patients received a 6-month Albendazole therapy while 14 patients received an indefinite treatment. All patients had a recurrence in a mean delay of 17.7 months. The only statistical difference between the two groups was the recurrence-free survival with a mean of 11.4 months for 6-month therapy patients and 27 months for long-term therapy patients (p=0.047).


Conclusion: Post-operative SCE Albendazole treatment duration might not affect neither the functional outcome nor the overall survival. Otherwise, our findings suggest indefinite Albendazole therapy following SCE surgery could not prevent local recurrence but might delay it compared with 6-month therapy.

Keywords:

Echinococcosis, Spine, Surgery, Albendazole, Recurrence, Survival

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. Deplazes P, Rinaldi L, Alvarez Rojas C. Global Distribution of Alveolar and Cystic Echinococcosis. Adv Parasitol. 2017;95:315‑493.
  2. Neumayr A, Tamarozzi F, Goblirsch S, Blum J, Brunetti E. Spinal cystic echinococcosis–a systematic analysis and review of the literature: part 1. Epidemiology and anatomy. PLoS Negl Trop Dis. 2013;7:2450.
  3. Neumayr A, Tamarozzi F, Goblirsch S, Blum J, Brunetti E. Spinal cysticechinococcosis--a systematicanalysis and review of the literature: part 2. Treatment, follow-up and outcome. PLoS Negl Trop Dis. 2013;7(9):e2458.
  4. Ozdemir H, Ogün T, Tasbas B. A lasting solution is hard to achieve in primaryhydatiddisease of the spine: long-termresults and an overview. Spine. 2004;29(8):932‑7.
  5. Brunetti E, Kern P, Vuitton D. Writing Panel for the WHO-IWGE. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop. 2010;114:1‑16.
  6. Baallal H, Kaddiri B, Mandour C, Gazzaz M, El Mostarchid B. Vertebral hydatidosis. Rev Prat. 2015;65(3):306.
  7. Hsairi M, Chahed M, Bchir A, Achour N. Épidémiologie de l’echinococcose en Tunisie. Tunisie Chirurgicale. 1997;1:5‑9.
  8. Ben Ismail R. L’hydatidose à Echinococcusgranulosus : Cycle biologique, dynamique de la transmission, cycles épidémiologiques en Tunisie et Implication lors de l’élaboration de stratégie de lutte. Tunisie Chirurgicale. 1997;1:10‑6.
  9. Aoun K, Bouratbine A. Epidemiological data concerning hydatidosis in Tunisia. Médecine et Maladies Infectieuses. 2007;37:40‑2.
  10. Craig P, Hegglin D, Lightowlers M, Torgerson P, Wang Q. Echinococcosis: Control and Prevention. Adv Parasitol. 2017;96:155‑8.
  11. Moro P, Schantz P. Echinococcosis: a review. Int J Infect Dis. 2009;13(2):125‑33.
  12. Altinörs N, Bavbek M, Caner H, Erdogan B. Central nervous system hydatidosis in Turkey: a cooperative study and literature survey analysis of 458 cases. J Neurosurg. 2000;93(1):1‑8.
  13. Sioutis S, Reppas L, Bekos A. Echinococcosis of the spine. EFORT Open Reviews. 2021;6(4):288‑96.
  14. Suntur B, Çavuş G. Pooled Analysis of 86 Published Spinal Hydatid Cyst Cases From Turkey. Mediterr J Infect Microb Antimicrob. 2019;8(1):7.
  15. Ladeb M, Riahi H, Mechri M. Imaging of Spinal Hydatidosis. Medical Radiology. 2021;237‑50.
  16. Erganis S, Sarzhanov F, Al F, Cağlar K. Comparison of Methods in the Serologic Diagnosis of Cystic Echinococcosis. Acta Parasitol. 2024;69(2):1122‑31.
  17. Steinmetz S, Racloz G, Stern R, Dominguez D, Al-Mayahi M, Schibler M, et al. Treatment challenges associated with bone echinococcosis. J Antimicrob Chemother. 2014;69:821‑6.
  18. Monge-Maillo B, Chamorro Trojeiro S, Lopez-Vélez R. Management of osseous cystic echinococcosis. Expert Rev Anti Infect Ther. 2017;15:1075‑82.
  19. Stojkovic M, Zwahlen M, Tegii A. Treatment response of cystic echinococcosis to benzimidazoles: a systematic review. PLoS Negl Trop Dis. 2009;3(9):e524.
  20. Todorov T, Mechkov G, Vutova K. Factors influencing the response to chemotherapy in human cystic echinococcosis. Bull World Health Organ. 1992;70(3):347‑58.
  21. Hamdan T, Al-Kaisy M. Dumbbell hydatidcyst of the spine: case report and review of the literature. Spine. 2000;25(10):1296‑9.
  22. McManus D, Gray D, Zhang W, Yang Y. Diagnosis, treatment, and management of echinococcosis. BMJ. 2012;(344):e3866.
  23. Junghanss T, da Silva A, Horton J, Chiodini P, Brunetti E. Clinical management of cysticechinococcosis: state of the art, problems, and perspectives. Am J Trop Med Hyg. 2008;79(3):301‑11.
  24. Pamir M, Ozduman K, Elmaci I. Spinal hydatid disease. Spinal Cord. 2002;40(4):153‑60.